Overall, comparing the respective in vivo efficacy by plotting % T/C values from the individual experiments, the broad tumor activity of M4205 across different KIT mutations becomes apparent whereas the SoC drugs imatinib, sunitinib, and ripretinib only cover some mutations at doses equivalent to clinical doses (Fig. 5G). The gene discussed is KIT; the disease is neoplasm.